PULMATRIX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.04 USD | -1.92% |
|
+2.53% | +9.68% |
| 03-28 | Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-13 | Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer | CI |
| Sales 2022 | 6.07M 486M | Sales 2023 | 7.3M 584M | Capitalization | 6.79M 544M |
|---|---|---|---|---|---|
| Net income 2022 | -18M -1.44B | Net income 2023 | -14M -1.12B | EV / Sales 2022 | -3.4 x |
| Net cash position 2022 | 34.77M 2.78B | Net cash position 2023 | 10.42M 834M | EV / Sales 2023 | -0.5 x |
| P/E ratio 2022 |
-0.71
x | P/E ratio 2023 |
-0.48
x | Employees | 22 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.92% | ||
| 1 week | +2.53% | ||
| Current month | +16.57% | ||
| 1 month | +20.66% | ||
| 3 months | +12.40% | ||
| 6 months | +9.10% | ||
| Current year | +9.68% |
1 week
1.94
2.10
1 month
1.562.19
Current year
1.552.34
1 year
1.553.14
3 years
1.5523.40
5 years
1.5560.80
10 years
1.552 910.00
| Managers | Title | Age | Since |
|---|---|---|---|
Teofilo Raad
CEO | Chief Executive Officer | 54 | 02/05/17 |
Peter Ludlum
DFI | Director of Finance/CFO | 68 | 17/04/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Batycky
BRD | Director/Board Member | 56 | 31/10/19 |
| Director/Board Member | 54 | 22/06/20 | |
Todd Bazemore
BRD | Director/Board Member | 53 | 30/09/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 2.04 | -1.92% | 6,762 |
| 25/04/24 | 2.08 | +2.97% | 2,103 |
| 24/04/24 | 2.02 | 0.00% | 4,090 |
| 23/04/24 | 2.02 | +0.25% | 815 |
| 22/04/24 | 2.015 | +1.27% | 8,481 |
Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm
More quotes
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Companyâs proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Companyâs product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Companyâs therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.
Calendar
15/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +9.68% | 7.45M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- PULM Stock
